Zeng L, Meng WJ, Wen ZH, Chen YL, Wang YF, Tang CW. Management and outcomes of surgical patients with intestinal Behçet’s disease and Crohn’s disease in southwest China. World J Clin Cases 2021; 9(16): 3858-3868 [PMID: 34141742 DOI: 10.12998/wjcc.v9.i16.3858]
Corresponding Author of This Article
Yu-Fang Wang, MD, Chief Doctor, Department of Gastroenterology, West China Hospital, Sichuan University, 37 Guo Xue Road, Wuhou District, Chengdu 610041, Sichuan Province, China. wangyufang04@126.com
Research Domain of This Article
Medicine, General & Internal
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Li Zeng, Zhong-Hui Wen, Yu-Fang Wang, Cheng-Wei Tang, Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Wen-Jian Meng, Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Yi-Long Chen, West China Biomedical Big Data Center, West China Hospital/West China School of Medicine, Sichuan University, Chengdu 610041, Sichuan Province, China
Author contributions: Zeng L collected the data, performed the research, and wrote the paper; Tang CW and Wang YF designed the research and supervised and reviewed the report; Meng WJ and Wen ZH designed the research and contributed to the analysis; Chen YL performed and verified statistical analysis.
Supported byNational Natural Science Foundation of China, No. 81270447.
Institutional review board statement: Ethical approval was obtained from the Biomedical Ethics Committee of West China Hospital, Sichuan University.
Informed consent statement: The patients provide signed informed consent to the study.
Conflict-of-interest statement: The authors declare that they have no conflict of interest to disclose.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yu-Fang Wang, MD, Chief Doctor, Department of Gastroenterology, West China Hospital, Sichuan University, 37 Guo Xue Road, Wuhou District, Chengdu 610041, Sichuan Province, China. wangyufang04@126.com
Received: November 30, 2020 Peer-review started: November 30, 2020 First decision: February 23, 2021 Revised: March 1, 2021 Accepted: April 6, 2021 Article in press: April 6, 2021 Published online: June 6, 2021
Core Tip
Core Tip: This real-world study was designed to identify effective postoperative treatment for patients with gastrointestinal involvement in Behçet's disease (GIBD) from the experience of Crohn’s disease (CD). Indication for first surgery was often acute gastrointestinal complications for GIBD patients, compared with patients with CD frequently undergoing purposed elective surgeries. Although no statistically significant difference was observed, patients with GIBD suffered more and earlier recurrences and reoperations than patients with CD. Awareness should be raised about the emergency condition of GIBD because it is more likely to be discounted than CD in clinics. Furthermore, they may require more aggressive treatment for more severe disease process postoperatively, like biological agents.
